Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Mounjaro® (tirzepatide),... Read more
Cardiometabolic Therapeutics & Regulatory Label Expansion: US FDA Clears Eli Lilly’s Mounjaro® (Tirzepatide) to Reduce Major Cardiovascular Events in Adults with Type 2 Diabetes – Outperforming Trulicity® by 8%
31/08/2026
Published by Pharma Biz
